Clinical Stage

Clinical Stage

Summary

1 2 3
Unmet Need
  • Prevention of Myopia progression in children aged 7 to 17
  • Reduce risk of ARDS Phase 1 Progressing to ARDS Phase 2 in Covid 19 Patients
  • Improve Patient Post Covid 19 recovery
  • Prevention of preterm birth in pregnant women
Status
  • 12 years named patient use trial completed in Denmark
  • First therapeutic product globally for myopia control
  • Investigator clinical trial in 15 patients in October 2020 completed successfully
  • Novel dosage form with 500% improved bio-availability
  • First product globally
Clinical Phase & IP
  • Phase 3 Clinical Trial in 2024
  • 20 Years IP
  • Phase 3 double blind 180 clinical study completed
  • Patent Filed September 2020
  • Patent Filed September 2019
  • Phase 3 Clinical Trial 2024
Molecule
  • 7 Methyl Xanthine
  • Ketone Ester
  • Algal DHA oil